BioAtla (BCAB) Projected to Announce Earnings on Thursday

BioAtla (NASDAQ:BCAB) will likely be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($8.50) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Friday, May 15th. The company reported ($4.22) earnings per share for the quarter, topping the consensus estimate of ($10.00) by $5.78.

BioAtla Stock Down 8.8%

Shares of BCAB opened at $3.22 on Thursday. The stock has a 50 day moving average price of $3.72 and a 200 day moving average price of $6.86. The company has a market capitalization of $5.35 million, a price-to-earnings ratio of -0.08 and a beta of 0.76. BioAtla has a 52-week low of $3.12 and a 52-week high of $71.50.

Analyst Upgrades and Downgrades

BCAB has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of BioAtla to a “hold” rating in a research report on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioAtla in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $200.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BCAB. Woodline Partners LP acquired a new position in BioAtla during the first quarter worth approximately $26,000. Jane Street Group LLC lifted its stake in BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after buying an additional 123,597 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of BioAtla by 9.1% in the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after acquiring an additional 162,647 shares during the period. Susquehanna International Group LLP boosted its holdings in shares of BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of BioAtla during the fourth quarter worth approximately $104,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.